They may have sneered at each other in the past, but collaborative efforts for translational research between academia and industry are happening, and they are working.

Applications for the Pfizer Australia Research Fellowships close on Monday

Michael Ashton joins Phosphagenics' board

A new cancer collaboration has been launched at Peter Mac in Melbourne, in association with Pfizer.

Apollo aborts mission, investment fund licensed, biotechs move into Phase II trials and NuSep sorts its sperm.

Cytopia goes into Phase II trials for vascular disrupting agent while Benitec licensee agrees to develop RNAi-based therapy for hepatitis C.

The 2008 Pfizer Australia Research Fellowships have been announced, bringing one Australian scientist home.

Florey research into schizophrenia mouse model finds exercise rescues abnormal chemical transmitter pathway.

When Merck announced last year it was buying Sirna Therapeutics for over US$1 billion, the world sat up and took notice. RNAi was now being seen as not only a revolution in our understanding but something with an unimaginable dollar value as well.

West Australian animal health company Stirling Products is developing a compound for increased muscle production and reduced fat in livestock that also has applications in porky pets.

Last year wasn't the best on record for the Australian biotechnology industry but this year and the next look much more promising. Share prices are up, investors are showing more interest and there are a lot of good stories to tell and sell.